The surgical mesh products are intended for transvaginal repair of pelvic organ prolapse.
The agency issued an order to remove the products from the market after determining that the manufacturers of the devices, Boston Scientific and Coloplast, did not demonstrate safety and efficacy of their devices.
Boston Scientific, which posted revenue of $9.8 billion in 2018, announced the anticipated financial hit in a U.S. Securities & Exchange Commission filing.
More articles on supply chain:
FDA braces for medical device shortages: 9 things to know
Reports of breast implant ‘illness’ spur FDA safety review
5 supply chain technologies to watch
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
